While tumor-secreted AMF typically promotes cell migration and correlates with tumor progression through AMF/AMFR signaling pathways [6,7,8], our findings show that specific AMF variants and derived peptides can, at higher concentrations, paradoxically inhibit cell growth and migration, potentially reducing MDR-associated effects. The gene discussed is AMFR; the disease is neoplasm.